Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
Yun-Kai Dai 1 , Hai-Na Fan 1 , Yong-Hong Hu 1 , Zhi-Min Zhao 1 2 , Chenghai Liu 1 2 3
Affiliations
Affiliations
1
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
2
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, China.
3
Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai, China.
Background and Aims: Although different kinds of traditional Chinese medicines could reportedly improve the efficacy of antiviral therapy on liver fibrosis caused by HBV, the problem of clinicians on how to choose the appropriate treatment strategies for the patients fails to be solved. This study aims at comparing and ranking different traditional Chinese medicine (TCM) therapies in the treatment of liver fibrosis due to chronic hepatitis B (CHB). Methods: Eight electronic databases were searched from their establishment to 17 Aug 2021. All included data and pooled odds ratio were used for network meta-analysis (NMA) and statistical analysis. The consistency was evaluated by the node-splitting analysis. The stability of results and source of heterogeneity were tested by sensitivity analysis. Different treatment strategies (regimens) in this network meta-analysis were ranked with the aid of surface under the cumulative ranking curve (SUCRA) probability value. Results: A total of 29 articles with 3,106 sufferers were recruited in this NMA. Results of SUCRA value rankings indicated that Fuzheng Huayu therapy or combined with entecavir had preferable effects in improving the clinical efficacy, recovering the level of hyaluronic acid, IV-C, ALT, ALB, and TBil, relieving the TCM symptoms including hypochondriac pain and poor appetite, regaining the width of portal vein and thickness of spleen, and lessening side effects. Apart from these, Ziyin Shugan therapy or combined with ETV could also be suitable to regain the level of laminin, PC-III, and AST, relieve fatigue and HBV-DNA conversion. Conclusion: This NMA confirmed the efficacy and safety of different treatment therapies for improving CHB liver fibrosis, including the serum biomarkers of live fibrosis and serum parameters for liver function, TCM symptoms, imaging indexes, HBV-DNA conversion rate, which offered the TCM practitioners crucial reference value on clinical medication.
Keywords: chronic hepatitis B liver fibrosis; clinical medication; randomized controlled trials; surface under the cumulative ranking curve; traditional Chinese medicines.
我建议你在这里说的话要非常小心,
Frontiers Media SA 是在开放获取的科学期刊上发表同行评审科学文章的出版商,涵盖整个学术界。 供学者了解最新信息的研究网络。
如果您不同意已发表的文章,您应该遵循以下科学标准:
1. 给论文作者写信; 或者
2. 给期刊编辑写一封信。
如果您对我的任何帖子有任何问题,请直接向我投诉或向版主投诉。
我对你的伪科学评论的评价很低。
I advise you to be very careful what you say here,
Frontiers Media SA is a publisher of peer-reviewed scientific articles across the entire spectrum of academia, in open-access scientific journals. Research network for academics to stay up-to-date with.
If you disagree with the published article, you should follow the scientific standards by:
1. write to the authors of the paper; or
2. write a letter to the editor of the journal.
If you have a problem with any of my postings, complain to me directly or complain to the moderator.
I have a very low opinion of your pseudo-scientific comments.作者: tim889 时间: 2022-9-3 00:41
本帖最后由 tim889 于 2022-9-2 11:30 编辑
StephenW 发表于 2022-9-2 03:39
我建议你在这里说的话要非常小心,
Frontiers Media SA 是在开放获取的科学期刊上发表同行评审科学文章 ...
显然,您不了解同行评审的概念。 这里的读者比你更老练,他们可以对这里发布的任何论文进行判断。 你吹嘘你的背景(“结论”?)谁知道你的背景是什么,但你的行为很糟糕。 我再说一遍,这篇论文的作者都被列出来了,所以请向他们投诉,除非你觉得自己不够格。 很明显你对乙肝领域一无所知。 这里的版主是博士,是HBsAg单克隆抗体方面的专家。
Frontiers 不是一个小期刊。 2021 年,Frontiers 是被引用次数第三多的出版商。 最近发表的文章的平均引用次数从 2020 年的 4.8 次增加到 2021 年的 5.5 次。 2021年,Frontiers文章被浏览和下载5.19亿次,总计19亿次。 这比上一年增长了 64%。 文章引用量也增加了 51%,总计 380 万次引用。
Obviously, you do not understand the concept of peer review. Readers here are more sophisticated than you are, they can exercise their judgment about any papers posted here. You boasted about your background("conclusion"?) who knows what your background is, but your conduct is abysmal. I repeat, the authors of this paper are all listed, so take your complaint to them, unless you feel too unqualified to do so. It is very obvious that you are ignorant in the field of HBV. The moderator here has a PhD and is an expert in monoclonal HBsAg antibodies.
Frontiers is not a small journal. In 2021, Frontiers was the 3rd most-cited publisher. Average citations increased from 4.8 in 2020 to 5.5 in 2021 for recent articles published. In 2021, Frontiers articles were viewed and downloaded 519 million times, totalling 1.9 billion overall. This is an increase of 64% over the previous year. Article citations also increased by 51%, totalling 3.8 million citations. 作者: tim889 时间: 2022-9-3 03:58
看来你不但自己paper没有读也读不懂,连最基本的就事论事也做不到。Frontiers in Pharmacology IF是多少你自己也查得到。如果对我的给的paper评论有异议大可以来进行学术讨论,不必要来搞道德绑架和人身攻击。我可以肯定的是,你不但没有受过良好学术训练,而且你的行为很槽糕。动不动就要教人做什么,这是很没有教养的行为。大家是啥水平,一目了然。
你否认人身攻击,否认诋毁他人,夸耀自己对科学方法的了解,确实应该受到谴责。
You deny making personal attacks, you deny denigrating others, you boast about your knowledge of scientific methods, indeed you should be condemned.作者: newchinabok 时间: 2022-9-3 12:40
Also, as I told you, you need to work on your gramma. The correct way of of using comma is either "Tim889 is a fraud. He needs to be unmasked." or "Tim889 is a fraud, and he needs to be unmasked."作者: tim889 时间: 2022-9-4 01:04
StephenW 发表于 2022-9-3 08:45
Tim889 是个骗子,他需要被揭穿。
Tim889 is a fraud, he needs to be unmasked.
“
2022年8月4日,Frontiers in Physiology 及Frontiers in Cell and Developmental Biology 共计撤回了中国学者13篇文章,其中Frontiers in Physiology 有9篇,Frontiers in Cell and Developmental Biology 有4篇;主要原因是涉嫌操纵同行评审;主要的单位包含天津市第一中心医院,中国人民解放军总医院,河南省胸科医院及中南大学等。
13篇文章撤稿声明都类似,如下:
出版商撤回引用的文章:出版后,出版商发现了在同行评审过程中使用虚假身份的证据。根据 Frontiers 的政策和出版道德委员会 (COPE) 指南进行的调查确认了虚假审稿人。
由于同行评审受到损害,调查包括对文章发表后的审查,得出的结论是,该文章本应被拒绝,因为它不符合Frontiers in Physiology 或者是Frontiers in Cell and Developmental Biology 的发表标准。
这不是Frontiers 系列第一次大批量撤稿中国学者文章,2022年1 月 11 日,瑞士出版社 Frontiers 在于 12 月 13 日宣布将进行广泛的内部调查并撤回造假论文后的一个月,撤回了Frontiers in Endocrinology,Frontiers in Oncology以及Frontiers in Physiolog上的至少 12 篇论文,其中 11 篇来自中国学者。
”作者: tim889 时间: 2022-9-4 02:59
所以在这种论坛上我从不讨论一个笼统的中药概念。有人说自己吃中药吃好了某个病,但其实同时又吃了别的药,你也说不清他到底是别的药治好了的(which is 大概率事件),或者是安慰剂效应。我在这里只是就事论事讨论具体的有据可查的文献。
如果你看了我后续的补充评论。这篇文献明显存在窜通审稿人的问题。撇开这个不讲,他里面所谓的扶正化淤对应了5种左右的方剂。荟萃分析的原理就是把不同研究的数据pool到一起去重新做统计分析。那么问题来了,首先何为“扶正化淤”是一个极其主观的标准,作者是基于什么把这些方剂归位一类的?其次,如果其中一种方剂的确有效但人数众多,另外四种方剂无效,那么就存在一种可能就是把5种方剂的数据pool到一起去之后,得出仍然会得出“扶正化淤”有效,这种情况就是统计上的type I error。最后,也是我发帖评论的初衷,战友看了文章去找医生要扶正化淤,世间扶正化淤的药方千千万万,每个中医开的都不一样,怎么能保证战友一定能吃到这5种中的一种药?更别说是5种药中的有效的那一种。难道要人把文献中的五种方剂全都吃上一遍?从这个角度来说这篇荟萃分析没有意义。
荟萃分析还有最大的缺陷就是基于的原论文研究的质量高低和sampling bias。这篇文献所引用的原文都是1分都不到的中文水刊。抛开这个不谈,研究会有个倾向性,就是如果做出来有效,那么就会倾向于发表,做出来无效根本就不会发表(尤其是当作者为了评职称有灌水的需求),所以你只是看不到无效的研究。这种情况下,由于multiple testing的问题自然有一部分因为纯随机的原因得出某中药有效的结论而被发表。而控制这类问题,样本量就关键。随着样本量上升,由于随机原因导致的有效性就会降低。但这篇文章所引用的原文献都是十几二十人的研究,由随机性导致的type I error之高可想而知。加上都是非随机双盲的研究,安慰剂效应和人为操纵的可能性大大提升。由于发表的偏向性问题,那么你自然会见到一对文献说某类方剂有用。